1. Yoo KH, Kim YS, Sheen SS, Park JH, Hwang YI, Kim SH, Yoon HI, Lim SC, Park JY, Park SJ, Seo KH, Kim KU, Oh YM, Lee NY, Kim JS, Oh KW, Kim YT, Park IW, Lee SD, Kim SK, Kim YK, Han SK. Prevalence of chronic obstructive pulmonary disease in Korea: the fourth Korean National Health and Nutrition Examination Survey, 2008. Respirology 2011;16:659-665.
2. Kim C, Kim Y, Yang DW, Rhee CK, Kim SK, Hwang YI, Park YB, Lee YM, Jin S, Park J, Hahm CR, Park CH, Park SY, Jung CK, Kim YI, Lee SH, Yoon HK, Lee JH, Lim SY, Yoo KH. Direct and indirect costs of chronic obstructive pulmonary disease in Korea. Tuberc Respir Dis (Seoul) 2019;82:27-34.
4. Korean Academy of Tuberculosis and Respiratory Disease; COPD Guideline Revision Committee. COPD guideline revised 2012: contracted version. Korean J Med 2013;84:464-479.
7. Lamprecht B, McBurnie MA, Vollmer WM, Gudmundsson G, Welte T, Nizankowska-Mogilnicka E, Studnicka M, Bateman E, Anto JM, Burney P, Mannino DM, Buist SA; BOLD Collaborative Research Group. COPD in never smokers: results from the population-based burden of obstructive lung disease study. Chest 2011;139:752-763.
8. Smith BM, Kirby M, Hoffman EA, Kronmal RA, Aaron SD, Allen NB, Bertoni A, Coxson HO, Cooper C, Couper DJ, Criner G, Dransfield MT, Han MK, Hansel NN, Jacobs DR Jr, Kaufman JD, Lin CL, Manichaikul A, Martinez FJ, Michos ED, Oelsner EC, Paine R 3rd, Watson KE, Benedetti A, Tan WC, Bourbeau J, Woodruff PG, Barr RG; MESA Lung, CanCOLD, and SPIROMICS Investigators. Association of dysanapsis with chronic obstructive pulmonary disease among older adults. JAMA 2020;323:2268-2280.
10. Kim TH, Rhee CK, Oh YM. Factors associated with indacaterol response in tuberculosis-destroyed lung with airflow limitation. Tuberc Respir Dis (Seoul) 2019;82:35-41.
11. Lange P, Celli B, Agusti A, Boje Jensen G, Divo M, Faner R, Guerra S, Marott JL, Martinez FD, Martinez-Camblor P, Meek P, Owen CA, Petersen H, Pinto-Plata V, Schnohr P, Sood A, Soriano JB, Tesfaigzi Y, Vestbo J. Lung-function trajectories leading to chronic obstructive pulmonary disease. N Engl J Med 2015;373:111-122.
13. Zhou Y, Zhong NS, Li X, Chen S, Zheng J, Zhao D, Yao W, Zhi R, Wei L, He B, Zhang X, Yang C, Li Y, Li F, Du J, Gui J, Hu B, Bai C, Huang P, Chen G, Xu Y, Wang C, Liang B, Li Y, Hu G, Tan H, Ye X, Ma X, Chen Y, Hu X, Tian J, Zhu X, Shi Z, Du X, Li M, Liu S, Yu R, Zhao J, Ma Q, Xie C, Li X, Chen T, Lin Y, Zeng L, Ye C, Ye W, Luo X, Zeng L, Yu S, Guan WJ, Ran P. Tiotropium in early-stage chronic obstructive pulmonary disease. N Engl J Med 2017;377:923-935.
18. Devereux G, Cotton S, Fielding S, McMeekin N, Barnes PJ, Briggs A, Burns G, Chaudhuri R, Chrystyn H, Davies L, Soyza A, Gompertz S, Haughney J, Innes K, Kaniewska J, Lee A, Morice A, Norrie J, Sullivan A, Wilson A, Price D. Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT. Health Technol Assess 2019;23:1-146.
21. Menezes AM, Wehrmeister FC, Perez-Padilla R, Viana KP, Soares C, Mullerova H, Valdivia G, Jardim JR, Montes de Oca M. The PLATINO study: description of the distribution, stability, and mortality according to the Global Initiative for Chronic Obstructive Lung Disease classification from 2007 to 2017. Int J Chron Obstruct Pulmon Dis 2017;12:1491-1501.
23. Song JH, Lee CH, Um SJ, Park YB, Yoo KH, Jung KS, Lee SD, Oh YM, Lee JH, Kim EK, Kim DK; KOLD, KOCOSS, and SNU airway registry investigators. Clinical impacts of the classification by 2017 GOLD guideline comparing previous ones on outcomes of COPD in real-world cohorts. Int J Chron Obstruct Pulmon Dis 2018;13:3473-3484.
26. Chun EM. Smoking cessation strategies targeting specific populations. Tuberc Respir Dis (Seoul) 2019;82:1-5.